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Radiation-induced autophagy is believed to represent a radioprotective mechanism of cancer cells. Thus,
its inhibition should support radiation treatment and increase its efficacy. On the other hand, there is evi-
dence that radiation alone or in combination with various chemical agents can induce autophagy that
results into increased cell death, especially within transformed apoptosis-resistant cells.
In this paper, besides description of autophagic process and its relation to cancer and radiotherapy, we
compared two contradictory radiosensitization approaches that employ inhibition and induction of
autophagy. In spite of the classical concept based on cytoprotective model, there is a plethora of recently
developed inducers of autophagy, which indicates the future trend in radiosensitization via modulation
of autophagy.
Because contemporary literature is conflicting and inconsistent in this respect, we reviewed the recent
studies focused on enhancement of sensitivity of cancer cells toward radiation in regard to autophagy,
revealing some striking discrepancies. The deeper the knowledge, the more complex this situation is.
To interpret results of various studies correctly one has to take into account the methodology of autop-
hagy assessment and also the fact that radiosensitization might be mediated by other than intrinsic
mechanisms related to autophagy. Notwithstanding, targeting autophagy remains an attractive anti-
tumor strategy.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 119 (2016) 265–275
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Autophagy is an evolutionarily conserved process enabling the
degradation and recycling of long-lived proteins or whole orga-
nelles during cellular stress conditions or at homeostasis basis.
The word autophagy comes from Greek auto-, ‘‘oneself” and pha-
gein, ‘‘to eat”. This intracellular degrading system is important for
maintaining physiological properties in healthy cells and its dereg-
ulation may lead to many different diseases, including cancer [1].
Autophagy can be activated as a response of various stimuli,
involving ionizing radiation (IR), DNA damage, chemotherapeutic
drugs, nutrient, oxygen and growth factor shortage [2,3] or depri-
vation of amino acids [4]. In some cases, autophagy plays role in
cell death, and thus it remains unclear whether autophagy is cyto-
protective mechanism or if it contributes to the cell death. Because
of the ability of autophagy to remove damaged proteins or orga-
nelles, it may paradoxically serve as a mechanism for maintaining
irradiated (or otherwise damaged) cells alive [5].There are many papers that cover the mechanism of autophagy
in detail [6–10]. Our aim is to provide a comprehensive review of
recent literature regarding modulation of autophagy as a promis-
ing tool in radiosensitization of cancer cells. Some authors hypoth-
esized that inhibition of autophagy is for radiosensitization of
tumor cells more beneficial than induction, because when
autophagy is inhibited, cancer cells cannot utilize autophagy as a
pro-survival process to overcome the stresses caused by anti-
cancer therapy, including IR. From a different point of view, it is
advantageous to induce autophagy, because it can restrict prolifer-
ation of tumor cells and contribute, via various mechanisms, to
radiosensitization. Above that, the situation is intricate due to
studies claiming that radiosensitization by inducers/inhibitors of
autophagy is processed via other than intrinsic mechanisms
related to autophagy.
Obviously, literature is in this respect very conflicting. Therefore
we reviewed recent studies that focused on radiosensitization and
we compared two different approaches that employ inhibition and
induction of autophagy.
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There are three known types of autophagy yet: (1) macroau-
tophagy, (2) microautophagy and (3) chaperone-mediated autop-
hagy (CMA) [11,12].
All of them use lysosome as a tool for degradation of substrates.
They differ from each other in mechanism by which cargo is deliv-
ered to the lysosome and each of them is also activated under dif-
ferent conditions [1,11,12]. Processes of microautophagy and
macroautophagy include participation of membrane. During
macroautophagy, a new double-membrane vesicle (autophago-
some) is created and surrounds the targeted cytosolic area [13].
Microautophagy is then mediated by lysosomal membrane itself
and cytosolic content is engulfed by lysosomal membrane directly
[14]. Opposed to the micro- and macroautophagy, CMA is based on
direct translocation of substrate across the lysosome membrane
via special proteins called chaperones. CMA is a highly selective
process which targets only cytosolic proteins. There are two major
steps in CMA; firstly, proteins determined to degradation are rec-
ognized and secondly, they are delivered through the membrane
of lysosome. Chaperone Hsc70 with co-chaperones recognizes a
specific peptide sequence of protein. Then protein/chaperone com-
plex interacts with lysosome-associated membrane protein type
2A (LAMP-2A) which is located on the cytosolic side of lysosomal
membrane. The full unfolding of the protein is required in order
to cross through the lysosomal membrane [15,16].
Macroautophagy (further referred to as autophagy) is a process
in which the double-membrane autophagosome (phagophore) is
formed to absorb molecules to be degraded. The whole machinery
of autophagy is regulated by autophagy related proteins (ATG)
coded by autophagy related genes (ATG) [17]. ‘‘Core” autophagic
complexes in mammals are: (1) ULK kinase complex (ATG1/unc-
51-like kinase), (2) class III PI3 kinase/vacuolar protein sorting 34
(Vps34) complex, (3) transmembrane protein ATG9-WIPI-1 and
(4) two ubiquitin-like conjugation systems ATG12 and LC3 (mam-
malian homolog for yeast ATG8) [7,18,19].
From the perspective of molecular biology, activation of the
ULK1/2 complex is necessary for proper induction of autophagy.
Under normal conditions mammalian target of rapamycin complex
1 – mTORC1 (complex of mTOR and regulatory-associated protein
of mTOR – RAPTOR) is activated and interacts with ULK complex
[19]. This interaction makes mTORC1 phosphorylate ATG13 and
ULK1/2 and then blocks kinase activity of ULK complex. Otherwise
inhibition of mTOR, caused by nutrient shortage or rapamycin
treatment, results in the disconnection of mTOR with the ULK com-
plex [20] and subsequent activation of ULK [18–21].
Nucleation is a step when the isolation membrane is being
formed. The main protein complex, which is required for this
process, is class III phosphatidylinositol-3-kinase (PI3K). The core
of this complex is built-up from proteins Vps34 (class III PI3K),
p150 (mammalian homolog for yeast Vps15) and Beclin-1
(mammalian homolog of yeast ATG6). Interaction of Vps34 and
Beclin-1 leads to the production of second messenger, phos-
phatidylinositol 3-phosphate (PI(3)P), which is important for fur-
ther development of autophagosome [22]. Beclin-1, the crucial
protein in modulation of autophagy, has an ability to either induce
or inhibit the process of nucleation in dependence on its binding
partners [2,21].
Once the isolation membrane is formed, it elongates and closes
on itself to form an autophagosome. This process is dependent on
two ubiquitin-like conjugation systems, ATG12 and LC3. ATG12
complex takes part in elongation, while LC3 complex is required
for the enclosing of double-membrane autophagosome [21].
ATG12 conjugation system involves proteins ATG12, ATG5 and
ATG16L which create a multimeric complex and mediate closureof the isolation membrane by LC3 conjugation system
[7,19,22,23]. Complex LC3 (mammalian homolog of yeast ATG8)
is a key complex for the final step of autophagosome formation
[24,25].
Maturation is the last step in autophagolysosome formation.
This step is divided into two sub-steps. At first, autophagosome
fuses with endosome to form a structure called amphisome. In
the second sub-step, amphisome merges with lysosome and pro-
duce autophagolysosome [12,13,21]. Degradation of
autophagolysosome content is performed by acidic lysosomal
hydrolases, which degrade also the inner membrane of
autophagolysosome. Products of degradation are released to the
cytosol and can be reutilized once again [24]. The process of mat-
uration is controlled by Beclin-1 and its binding partners [21].
Autophagy meets cancer
Development of cancer is related to six biological capabilities,
which are characteristic as hallmarks of cancer. They include sus-
taining proliferative signaling, evading growth suppressors, resist-
ing cell death, enabling replicative immortality, activating invasion
and metastasis, and inducing angiogenesis [26]. Angiogenesis is
the most significant one, in context of autophagy, because new
blood vessels provide nutrition for cancer cells. Defects in angio-
genesis and also increased need for ATP and anabolic substrates
for biosynthetic processes lead to nutritional misbalance of cancers
[27]. This nutritional misbalance developed in cancer cells might
be suppressed by activation of autophagy.
Autophagy is in tumor cells activated as a response to various
stresses, including starvation, growth factor deprivation, hypoxia,
damaging stimuli and proteasome inhibition. The different roles
of autophagy in cancer cells seem to depend on tumor type, stage,
and genetic context. It is now well established that autophagy can
act as a tumor suppressor in early stages of tumorigenesis and as a
tumor promoter in developed tumors [28,29]. At the beginning of
cancer formation, autophagy suppresses the initiation and further
tumor progression. The first reference of autophagy as a tumor
suppressor appeared in 1999. It was declared through genetic
studies of Beclin-1 [30]. Further examinations on mice with allelic
loss of the essential autophagy gene BECLIN1 (BECN1; also known
as ATG6) revealed development of hepatocellular carcinomas,
which clearly demonstrated the necessity of this gene [31,32].
The liver tumors burdened by loss of BECN1, suffered from obligate
haploinsufficiency and could not tolerate the complete loss of
BECN1 and autophagy. A higher amount of spontaneous tumors
appeared in mice lacking one copy of BECN1 [31,32]. Also
autophagy-deficient BECN1+/ and ATG5/ immortalized baby
mouse kidney epithelial cells which were reported to be more sus-
ceptible to DNA damage, gene amplification, chromosome instabil-
ity, and aneuploidy, all of which are clinically associated with
tumor progression and poor prognosis [33]. In the initial phase of
tumor formation, autophagy plays several roles; it (1) inhibits
necrosis and inflammation, (2) prevents oxidative stress and geno-
mic instability, (3) contributes to tumor cell death, (4) modulates
the anti-tumor immune response, and (5) inhibits metastasis [34].
Rapidly growing and developed solid tumors are highly exposed
to nutrient, growth factor, and oxygen deprivation due to inade-
quate vascularization. Tumor growth is conditioned via neovascu-
larization in order to pass the metabolic barrier and expand in size.
When this requirement is not fulfilled under physiological condi-
tions, the starving cells die by apoptosis [35]. In tumors with defec-
tive apoptosis, sustained autophagy possibly contributes to cell
survival. Autophagy is localized in metabolically stressed, hypoxic
regions of solid tumors and can maintain survival for several weeks
[29,33,36].
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how do cells recognize nutrient starvation? It seems that tumor
cells can recognize the amount of AMP. AMP-activated protein
kinase (AMPK) is well described in mediating various stress signals
including hypoxia, nutrient starvation, and physical stresses [37].
Only a few minutes are required to recognize nutrient starvation,
followed by induction of autophagy. Under conditions of nutrient
deprivation, autophagy can also suppress latent apoptotic pro-
gram, prevent cell death, and thus preserve cellular homeostasis
[38]. Indeed, BrafV600E autophagy-deficient tumor cells without
alleles of the essential autophagy gene ATG7 were unable to sur-
vive the starvation. Thus, due to the absence of internally supplied
glutamine, provided by autophagy-mediated recycling of proteins,
ATG7-lacking cells were reliant on exogenously supplied glu-
tamine. It seems that autophagy may be a mechanism to provide
the tumor cells with glutamine and sustain BrafV600E tumor growth
and metabolism [29].
Hypoxia (oxygen concentration <3%) and anoxia (oxygen con-
centration <0.1%) are both strong inducers of autophagy. Oxygen
deprivation can induce autophagy also in the absence of additional
stress such as glucose deprivation or serum withdrawal. Induction
of autophagy is in human tumor cells performed through various
mechanisms [20]. Hypoxia-induced autophagy depends on
hypoxia-inducible factor (HIF), while anoxia-induced autophagy
is HIF-independent. Upon moderate hypoxia (1–3% oxygen), HIF
activates the transcription of BNIP3 and BNIP3L, two proteins which
activate further autophagic processes [39]. The role of the BNIP3 in
hypoxia-induced autophagy has been examined by Tracy et al.,
who proposed that levels of BNIP3 are modulated by RB tumor sup-
pressor and the amount of BNIP3 is crucial for the type of cell death
[40]. Moreover, Shaaf et al. reported that protective autophagy
occurred during hypoxia as a result of ULK1 upregulation which
is associated with hypoxia tolerance. Increased level of ULK1 was
unfolded protein response- (UPR-) and HIF-1a-pathways-
dependent [41]. Additional pathways have also been implicated
in hypoxia-induced autophagy. Papandreou et al. showed that
hypoxia-induced autophagy is independent of nutrient depriva-
tion, HIF-1a activity, and expression of BCL-2/adenovirus E1B
19 kDa interacting protein 3 (BNIP3). Especially AMP-activated
protein kinase (AMPK) signaling pathway was linked with the
induction of autophagy under oxygen shortage [42]. Other HIF-
independent signaling pathways have been studied by Rouschop
et al., who described the importance of UPR protein in activation
of autophagy in hypoxic cells. UPR maintains levels of MAP1LC3B
and ATG5 through PKR-like ER kinase (PERK) and thus promotes
hypoxia tolerance [43].
The withdrawal of growth factors is another potent inducer of
autophagy. Growth factors determine the formation of tumors
and promote cell survival by maintaining the ability of cells to take
up sufficient nutrients to continue ATP production. Thus, low level
of growth factors may lead to an impaired development of cancer.
Autophagy reflects these conditions and supports survival of
growth factors-deprived cells [44]. Autophagic process is then reg-
ulated through the mTORC1-unc-51 like autophagy activating
kinase 1 (ULK1) complex interactions. When mTORC1 activity is
suppressed due to growth factor withdrawal, ULK1 complex
becomes derepressed and autophagy is induced [45].
Tumor cells are assumed to prefer glycolysis, which means that
they mainly generate energy by non-oxidative breakdown of glu-
cose, even when oxygen is present to respire properly. They display
high level of glucose uptake and lactate production as an end pro-
duct of glucose fermentation in contrast to ‘‘healthy” cells, which
use oxidative breakdown with pyruvate as an end product of respi-
ration. This form of aerobic glycolysis is termed the ‘‘Warburg
Effect” [46]. High demands on energy supply in cancerous cells
may lead to a severe shortage of energy. Tumor cells that are notable to obtain energy can die by necrosis. Products of necrosis lead
then to formation and accumulation of reactive oxygen species
(ROS), which induce oxidative stress in the tumor microenviron-
ment. Bystander tumor cells react to this harmful situation by
inducing autophagy to remove ROS together with damaged cellular
organelles and use this housekeeping program to support their
own growth [47].
Anoikis is a form of programed cell death (PCD) that occurs
when anchorage-dependent cancer cells detach from the sur-
rounding extracellular matrix (ECM) with the ability to become
invasive and to spread into the distant tissues. Under physiological
conditions, cells stay close to the tissue to which they belong and
share essential signals for growth or survival. When cells are
detached from the ECM, cell signalization is interrupted, and they
may undergo anoikis. Autophagy is largely used by cancer cells in
order to avoid anoikis and induce the later stages of cancer pro-
gression, such as dissemination and metastasis [48,49]. Subpopula-
tion of cells within tumors, termed cancer stem cells, is responsible
for tumor recurrence and metastasis. They may generate tumors
through processes of self-renewal and differentiation into multiple
cell types and some of them may persist in tumors as a distinct
population and cause relapse and metastasis. It seems that autop-
hagy plays an important role also in the survival, differentiation
and self-renewal of cancer stem cells [49,50].
Taken together, autophagy provides cells a resilient capacity for
regeneration, which is proved by increasing cell size and
resumption of cell proliferation after the removal of stressors.
Autophagy-deficient cells are not only capable of tolerating
metabolic stress but they also fail in the process of recovery. This
suggests that autophagy is crucial process in progression and resis-
tance of tumor cells [51].The role of autophagy in irradiated cancer cells
Radiation treatment triggers an enormous amount of stress. If
applied on cancer cells, it leads to conditions which are not suitable
for proper development of these cells and thus induces autophagy.
There are several studies which describe that clinically relevant
doses of radiation promote autophagy in tumor cells [52–55].
These studies assume that autophagy, induced as a reaction on
stressful conditions, has a protective role in cancer cells. It presum-
ably prevents tumor cells from cell death through apoptosis which
cooperates with autophagy via convoluted crosstalk between
autophagic and apoptotic signaling pathways [56,57]. It is very
likely that the key role of autophagy within radiation therapy is
not in degradation of cellular components and providing nutrients
and metabolic precursors, but in elimination of toxic species.
Tumor cells are not actually experiencing deficiency of metabolic
materials, but they are endangered by toxic species, such as free
radicals and possibly damaged and misfolded proteins or orga-
nelles, which should be eliminated [58]. IR induces autophagy via
hypophosphorylation of mTOR [59]. It leads to decreased phospho-
rylation of mTOR at its autophosphorylation site (Ser2481) and
subsequent activation of autophagy. Complete mechanism of
mTOR hypophosphorylation has to be clarified, but it is possible
that activation of the ataxia telangiectasia mutated (ATM) protein
kinase following the IR exposure leads to activation of Liver Kinase
B1 (LKB-1) and to inhibition of mTOR through an ATM/LKB-1/
AMPK/Tuberous Sclerosis Complex 2 (TSC2) pathway [60]. Soto-
Pantoja et al. described on CD47 Jurkat T cells and CD47/ mur-
ine lung endothelial cells that transmembrane protein receptor
CD47 has a substantial role in activation/inhibition of autophagic
response to IR. Inhibition or complete shortage of this protein
resulted into increased autophagosome formation and cell protec-
tion to radiation stress [61].
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and other external stress factors has been known for years. How-
ever, it was described in some studies that autophagy plays also
a role in cell death as a response to a variety of chemotherapeutic
agents as well as to IR [62]. It seems that some authors support the
idea of autophagy as a mode of radiosensitization more than pro-
tection from radiation injury and cell death [63].
There has been a tendency to consider radiation-induced autop-
hagy as a cytoprotective mechanism, which has (from its origin) a
presumable role in radioresistance of cancer cells. However, this
conclusion seems to be unconvincing when we take into account
a wide spectrum of tumor cell lines where autophagy is induced.
Above that, there is no clear evidence that autophagy induction
is directly linked with radiosensitization and that fact is limited
only to tumor cells that might be considered as radioresistant.
Hence it is reasonable to explore other roles that autophagy might
have; i.e. besides the cytoprotective one, the cytostatic or even
cytotoxic [64].Inhibition of autophagy: does the original idea really work?
The first observation linked with autophagy led to a presump-
tion that autophagy is a cytoprotective mechanism in tumor cells.
Hence, the first apparent approach to sensitize cancer cells to IR
was by using the autophagy inhibitors. The following section is
dedicated to inhibition of autophagy in the context of
radiosensitization.
Chloroquine (CQ) together with 3-methyladenine (3-MA) is
among the most widely used autophagy inhibitors. By blocking
the fusion of autophagosome and lysosome, CQ inhibits later stages
of autophagy, while 3-MA interferes with PI3K pathway. RT, as well
as chemotherapy with 5-fluorouracil (5-FU), induces autophagy in
colorectal cancer cells. Schonewolf et al. found out that inhibition
of RT-induced autophagy (8 Gy) by CQ radiosensitized p53-
deficient HT-29 cells, but not p53-wild type (p53-wt) HCT-116
cells. Treatment of HT-29 cells with CQ also improved the effect
of combined chemo-RT [65].
ATM kinase affects many pathways, including autophagy, and
therefore is among the suitable targets for radiosensitization. Tou-
lany et al. reported that ATM can stimulate autophagy after IR.
They examined effect of cisplatin, which causes DNA damage, in
lung cancer cell lines A549 and H460. H460 cells were sensitized
to IR by cisplatin, but on the contrary A549 cells were not. In
A549 cells, cisplatin activated ATM and autophagy, which led to
radioresistance. Further experiments with combining the inhibi-
tors of ATM pathway (KU-55933) and autophagy (CQ) resulted in
radiosensitization of both A549 and H460 cells to IR. Importantly,
treatment of H460 and A549 cells with cisplatin and CQ did not
influence their radiosensitization, underlining the role of ATM [66].
Jin et al. published that application of autophagy inhibitors CQ
or 3-MA may sensitize human cervical cancer cells (HeLa) and
human breast cancer cell lines (MDA-MB-231, MCF-7) to high lin-
ear energy transfer (high-LET) radiation. Irradiated tumor cells also
displayed a dose-dependent increase in the level of autophagy.
Furthermore, pre-treatment of cells by 3-MA accelerated apoptotic
cell death and enhanced radiosensitization of tumor cells [67].
To assess the role of autophagy in radiosensitization, Chaa-
chouay et al. used two different breast cancer cell lines: radioresis-
tant MDA-MB-231 and radiosensitive HBL-100 cells. Induction of
autophagy by radiation was observed in MDA-MB-231 but not in
HBL-100, suggesting protective role of autophagy contributing to
the mechanism of radioresistance in MDA-MB-231 cells. Radiore-
sistant MDA-MB-231 cells treated by either CQ or 3-MA and IR
showed increased radiosensitization represented by a significant
decrease in clonogenic survival [68].In addition, hypopharyngeal carcinoma cells (FaDu cells) irradi-
ated by 2 or 4 Gy and treated with 3-MA showed reduced clono-
genic survival and more severe DNA damage than untreated
cells. Combined treatment with 3-MA and IR led to increased
radiosensitization of FaDu cells, due to dose-dependent G2/M cell
cycle arrest enhancement, as well as escalation in p62 production.
Level of cyclin B1, on the other hand, demonstrated dose-
dependent decrease [69].
Cheng et al. examined the role of p53, which could potentially
regulate radiosensitivity in H1299 non-small cell lung cancer cells
(NSCLCC). 3-MA and Z-VAD-FMK were used as autophagy and
apoptosis inhibitors. Decreased cell viability was observed in irra-
diated (8 Gy) H1299-p53 cells (p53-wt). On the contrary, inhibition
of apoptosis by Z-VAD-FMK led in the identical cells to increase in
cell viability. Furthermore, Z-VAD-FMK-mediated inhibition of
apoptosis caused enhancement of autophagic activity in H1299-
p53, but not in H1299 (p53-deficient) cells. These outcomes sug-
gest that pre-treatment of cells by 3-MA may lead to increased
radiosensitivity [70].
Another approach used in radiosensitization of cancer cells is
the targeting of signal transducer and activator of transcription 3
(STAT3) signaling pathway by WP1066 inhibitor or short hairpin
RNA plasmid (shRNA). Cell permeable WP1066 is an analog of tyr-
osine kinase inhibitor Tyrphostin AG 490, which selectively inhi-
bits the epidermal growth factor receptor (EGFR). Both WP1066
and STAT3 shRNA radiosensitized human malignant glioma cells
(U251) probably due to induction of intrinsic apoptosis, which
can contribute to sensitization toward IR. Moreover, inhibition of
STAT3 led to increased autophagic activity. Additionally, clono-
genic survival of glioma cells was reduced by using autophagy
inhibitor 3-MA or knockdown of one of major autophagic protein
ATG5 by siRNA [71].
PI3K/Akt pathway is one of the most common signaling path-
ways activated as a response to IR in cancer cells. It is an upstream
regulator of mTOR and controls cell growth and proliferation
[72,73]. PI3K/Akt pathway may also contribute to the radioresis-
tance of tumor cells during cancer therapy [72,74]. PI3K/Akt/mTOR
pathway is a crucial regulator of autophagy. Many researchers use
this pathway to modulate autophagic process in order to under-
stand radioresistance and radiosensitization of cancer cells [75,76].
NVP-BEZ-235 (BEZ235) is a dual inhibitor of PI3K/mTOR path-
way, which induced autophagy and caused radiosensitization of
SQ20B head and neck cancer cells, U251 glioblastoma cells and also
increased in vivo radiation response of SQ20B xenografts. Cerniglia
et al. proved that BEZ235 alone may lead to the attenuation of
radiosensitization, but pre-treatment of SQ20B cells with CQ or
3-MA followed by BEZ235 treatment resulted into decreased
clonogenic survival compared to mere BEZ235 treatment [77].
In contrast to the previous studies, Schaaf et al. published that
radioresistance of cancer cells is independent of canonical autop-
hagy that involves lysosomal degradation. Experiments with CQ
on colorectal adenocarcinoma (HT29, HCT116), mammary adeno-
carcinoma (MCF7, MDA-MB-231) and lung carcinoma (A549) cells
showed that CQ truly inhibits autophagy but does not increase the
radiosensitization. The anti-tumor effect of CQ is mediated via
reduction of the hypoxic radioresistant cell population within the
tumor, rather than affecting intrinsic radiosensitivity of cancer
cells. Even more surprising were other experiments with 3-MA
which displayed potential radiosensitizing effect with no signs of
autophagy inhibition leading to a conclusion that 3-MA does
impact mechanisms which induce radiosensitization but are unre-
lated to autophagy itself [78]. These were unexpected and impor-
tant observations revealing additional effects, which enable
misinterpretation. Such reports open space for an extensive dispu-
tation about conclusions of many studies regardless of publishing
in prestigious journals.
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on the small fraction of hypoxic HCT116 colorectal adenocarci-
noma xenografts but apparently not via inhibition of autophagy
or intrinsic change in cellular radiosensitivity. Instead, they pro-
claimed enhancement of tumor radiosensitivity via reduction in
the fraction of viable radiation-resistant hypoxic cells in the CQ-
treated tumors. However, this effect is limited to hypoxic condi-
tions and was not observed in normoxic cells [43].
Commonly, inhibition of PI3K/Akt/mTOR pathway is linked with
radiosensitization with inducing autophagy. However, Chang et al.
found out that a combination of dual inhibitors of PI3K and mTOR
(BEZ235 and PI-103) and IR (6 Gy) can efficiently suppress tumor
colony growth, induce more apoptosis, abrogate cell-protective
autophagy and improve radiosensitivity of three prostate cancer
cell lines (PC-3RR, DU145RR and LNCaPRR). They also found that
a combination of dual inhibitors (BEZ235 and PI-103) with IR
greatly changed cell cycle distribution, caused higher cell cycle
arrest in G2/M phase (the most sensitive phase to radiation) and
reduction of cells in G0/G1 and S phases (the most resistant phases
to radiation) compared with combination of single inhibitors
(BKM120 and rapamycin) with IR [72].
Bafilomycin A1 is a widely used inhibitor of autophagy. It pre-
vents maturation of autophagic vacuoles by inhibiting fusion
between autophagosome and lysosome. He et al. studied tricho-
statin A (histone deacetylases inhibitor – TSA) as a potential
radiosensitizing agent on human colon cancer cells (HCT-116).
They found out that TSA radiosensitized HCT-116 cells, but also
increased autophagy which hampered the radiosensitizing effect.
Further pre-treatment with Bafilomycin A1 inhibited cytoprotec-
tive autophagy and increased level of apoptotic proteins Bax and
Bak together with caspase-3 ergo triggered apoptosis. Thus, inhibi-
tion of cytoprotective autophagy was proved to enhance the
radiosensitization of HCT-116 cells [79].
IR induces autophagy in various cancer cell lines. Apel et al.
observed accumulation of autophagic vesicles in MDA-MB-231
breast cancer cells with mutant p53 proteins; HTB43 pharyngeal
cancer cells with mutant p53, HTB35 cervical squamous cell carci-
noma cells with mutant p53 and A549 lung cancer cells transfected
with an Ectysone-inducible mutant p53 construct. Accumulation of
autophagic vesicles was apparent 1–12 h after IR exposure; further-
more, there was a dose-dependent (2, 4 and 10 Gy) increase in
expression of ATG genes. Importantly, formation of autophagosome
after IR was not dependent on p53 status or level of radioresistance.
Knocking down of autophagy-related genes (BECN1, ATG3, ATG4B,
ATG4C, ATG5 and ATG12) prevented formation of autophagosomes
in all tested cell lines, but the same dose of IR had different impacts
on clonogenic survival of radioresistant and radiosensitive cells.
Apel et al. suggest that autophagy can serve as a cytoprotective
mechanism and its inhibition leads to radiosensitization. Neverthe-
less, clonogenic survival can be increased by autophagy inhibition
in untreated radioresistant cells [52].
Recently two new autophagic inhibitors, Spautin-1 and Lys05,
have been described. Spautin-1 targets the activity of two
ubiquitin-specific peptidases, USP10 and USP13 and causes PI3K
complex degradation. Park et al. examined the role of Beclin-1
and UVRAG in managing DNA damage and repair response to can-
cer therapy in colorectal cancer cells (HT-29, DLD1). They reported
that inhibition of autophagy by Spautin-1 increased cell death due
to accumulation of DNA damage [80]. In addition, a new inhibitor
Lys05 was discovered by McAffee et al. Lys05 is a dimeric form of
CQ which has a potential to accumulate in the lysosome and block
autophagy more effectively compared to hydroxychloroquine
(HCQ). Recently, it exhibited more potent anti-tumor activity as a
single agent both in vitro and in vivo. Despite this fact, further
experiments with this substance with regards to radiosensitization
are still needed [81,82].Inhibition of cytoprotective autophagy was the original idea
leading to radiosensitization of cancer cells. Many studies have
been performed in order to sensitize tumor cells toward IR result-
ing in various outcomes. It has been proved that radiosensitization
of cancer cells toward IR using autophagy inhibitors is possible, but
definitely not in all types of cancer. The situation is obviously intri-
cate due to the unexpected conclusions of the studies such as
Schaaf et al. [78], which opens space for disputation.
We must bear in mind that it depends greatly on the inhibitors
and particular properties of cancer cell lines used in order to con-
clude, whether targeting autophagy via inhibition would be the
right approach to radiosensitize tumor cells.Activation of autophagy: new opportunities for
radiosensitization
Many experiments with inhibitors of autophagy have been per-
formed, but so far, not all of thempresented the expected outcomes.
Another group of studies focused on radiosensitization of cancer
cells describes activation of autophagy (mostly in combinationwith
other compounds) as a process leading to their radiosensitization.
However, there is a question which still remains unanswered. Do
the cancer cells die with autophagy or by autophagy?
PI3K/Akt/mTOR inhibition conceivably appears among the pri-
mary targets for autophagy induction. For instance, it has a signif-
icant effect on cisplatin-resistant NSCLCC, CDDP-R. Combination of
BEZ235 with IR led to enhanced formation of autophagosomes
which was monitored in real time via fluorescence microscopy.
Pre-treatment by BEZ235 radiosensitized both parental (NCI-
H460-Luc2) and radioresistant (CDDP-R H460-Luc2) cell lines. In
addition to in vitro results, this combination induced a dramatic
tumor growth delay in a mouse xenograft model [83].
Choi et al. radiosensitized lung cancer cell lines (A549, H460
and H1299) using siRNA (specific for either EGFR or K-RAS) and
variety of kinase inhibitors: PD98059 (c-RAF), UO126 (mitogen-
activated protein/ERK kinase kinase), LY294002 (PI3K), and PI-
103. Inhibition of PI3K and mTOR signaling by PI-103 effectively
increased the radiosensitivity of A549 and H460 cells. It is likely
that combination of PI-103 and IR led to mixed modes of cell death
[84]. Similar endpoints were observed in another study by No et al.
using PI-103 dual inhibitor in combination with IR in order to
radiosensitize SKBR3 breast cancer cells resistant to HER-2 inhibi-
tors [85].
mTOR was also targeted indirectly by nelfinavir and borte-
zomib, which primarily cause endoplasmic reticulum (ER) stress
in cancer cells and thus induce sestrin-2 (SESN2), a known mTOR
inhibitor. Generally, inhibition of mTOR leads to activation of
autophagy. Brüning et al. applied this autophagy activating strat-
egy and they successfully radiosensitized breast cancer (HTB-
131), ovarian cancer (HTB-161), and cervical adenocarcinoma
(HeLa) cell lines [86].
Furthermore, mTOR inhibition by rapamycin allowed overcom-
ing of radioresistance in glioma-initiating cells (GIC). This combi-
nation effectively blocked the tumor growth and associated
mortality in mice after intracerebral grafting of human GIC [87]
and proliferation of lung cancer cells (A549) [88]. Palomid 529
(also known as P529, an mTORC1/mTORC2 inhibitor) was com-
bined with IR and tested on a wide panel of prostate cancer models
and xenografts. Its radiosensitizing effect is based on GSK-3b,
cyclin-D1, and c-myc modulation. In addition, delayed DNA repair,
autophagy and tumor senescence were involved [89].
Anbalagan et al. used IR to overcome resistance to standard
cytotoxic chemotherapy on a panel of different renal carcinoma
cell lines and found it effective in combination with two autophagy
inducers: STF-62247 (interferes with Golgi-ER transport via
Table 1
An overview of discussed radiosensitizers. Substances are divided into two groups based on assumption of their impact on autophagy. For each substance the mechanisms of
action and relation to radiation are described together with cell type used in the particular study and relevant reference.
INHIBITORS of autophagy Mechanism of action Relation to the radiation Type of cells
3-Methyladenine Inhibits PI3K signaling pathway Pre-treatment by 3-MA led in combination with IR to
radiosensitization of breast and cervical cancer cells
MDA-MB-231, HBL-100,
HeLa
[77,78]
Pre-treatment by 3-MA led in combination with IR to
radiosensitization of hypopharyngeal carcinoma cells
FaDu [69]
Combined treatment with Z-VAD-FMK radiosensitized
NSCLCC
H1299 [70]
Combined treatment with WP1066 and STAT3 shRNA
radiosensitized malignant glioma cells
U251 [71]
Combined treatment with BEZ235 radiosensitized head and
neck cancer cells
SQ20B [77]
Pre-treatment by 3-MA led in combination with IR to
radiosensitization of colorectal adenocarcinoma, mammary
adenocarcinoma and lung carcinoma cells
HT29, HCT116, MCF7,
MDA-MB-231, A549
[78]
Bafilomycin A1 Prevents fusion of autophagosomes
and lysosomes
Combined treatment with TSA radiosensitized colon cancer
cells via increased level of apoptosis
HCT-116 [79]
Chloroquine Impairs fusion of autophagosomes
and lysosomes, and inhibits
lysosomal protein degradation
Combined treatment with 5-FU radiosensitized colorectal
cancer cells
HCT-116, HT-29 [65]
Combined treatment with KU-55933 radiosensitized lung
cancer cells
A549, H460 [66]
Pre-treatment by CQ led in combination with IR to
radiosensitization of breast cancer cells
MDA-MB-231 [68]
Combined treatment with BEZ235 radiosensitized head and
neck cancer cells
SQ20B [77]
Pre-treatment by CQ led to inhibition of autophagy but not
to radiosensitization of colorectal adenocarcinoma,
mammary adenocarcinoma and lung carcinoma cells
HT29, HCT116, MCF7,
MDA-MB-231, A549
[78]
Pre-treatment by CQ led in combination with IR to
radiosensitization of colorectal adenocarcinoma xenografts
HCT116 [43]
Lys05 Accumulates within and deacidifies
the lysosomes
No experiments have been performed yet [81]
siRNA Downregulates the major autophagic
proteins
Combined treatment with WP1066 and STAT3 shRNA
radiosensitized malignant glioma cells
U251 [71]
Pre-treatment by siRNA led in combination with IR to
radiosensitization of various cancer cell lines
MDA-MB-231, HTB43,
HTB35, A549
[52]
Spautin-1 Promotes degradation of Beclin-1
subunit of PI3K complex by
inhibiting the activity of USP10 and
USP13
Pre-treatment by Spautin-1 led in combination with IR to
radiosensitization of colorectal cancer cells due to
accumulation of DNA damage
HT-29, DLD1 [80]
INDUCERS of autophagy Mechanism of action Relation to the radiation Type of cells
1L-6-hydroxymethyl-
chiro-inositol 2(R)-2-O-
methyl-3-O-
octadecylcarbonate
Downregulates Akt signaling
pathway
Combined therapy with IR radiosensitized malignant glioma
cells
U87-MG, U87-
MGDEGRF
[73]
Antisense oligonucleotides Abrogates the activity of DNA-PKcs Pre-treatment by antisense oligonucleotides led in
combination with IR to radiosensitization of malignant
glioma and fibroblast cells
M059K, U373-MG,
T98G, MRC5
[97]
Apogossypolone Inhibits the binding of Bcl-2 to
Beclin-1
Pre-treatment by ApoG2 led in combination with IR to
radiosensitization of nasopharyngeal carcinoma cells and
mice xenografts
CNE1, CNE2 [93]
Bortezomib Cause ER stress and thus induce
SESN2, an mTOR inhibitor
Combination of these two activators with IR led to
radiosensitization of ovarian, breast and cervical cancer cells
HTB-131, HTB-161,
HeLa
[86]
Nelfinavir
Calcitriol Inhibits PI3K/Akt/mTOR signaling
pathway
Pre-treatment by calcitriol led in combination with IR to
radiosensitization of breast tumor cells
ZR-75-1 [98]
MCF-7 [99]
Cisplatin Induces PI3K activation signaling
pathway and decreases the level of
Bcl-2 proteins
Combined therapy with IR radiosensitized lung cancer cells
and mouse xenografts
A549 [96]
EB1089 Inhibits PI3K/Akt/mTOR signaling
pathway
Pre-treatment by EB1089 led in combination with IR to
radiosensitization of breast tumor xenografts
MCF-7 [100]
Everolimus Inhibits mTOR signaling pathway Pre-treatment by everolimus led in combination with IR to
radiosensitization of Ras-transformed cells
RK3E/tv-a [91]
Combined treatment with Z-DEVD radiosensitized lung
tumor xenografts
H460 [92]
Lapatinib Inhibits ErbB1/ErbB2 signaling
pathway
Combination of lapatinib and obatoclax led to
radiosensitization of breast cancer cells
BT474, MCF-7, HCC38,
BT549, HCC1187, MDA-
MB-453, MDA-MB-175
[94]
Obatoclax Inhibits activity of Bcl-2/Bcl-XL/Mcl-
1 proteins
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Table 1 (continued)
INHIBITORS of autophagy Mechanism of action Relation to the radiation Type of cells
NVP-BEZ-235 Inhibits PI3K/Akt/mTOR signaling
pathway
Pre-treatment by BEZ235 led in combination with IR to
radiosensitization of lung cancer cells
NCI-H460-Luc2, CDDP-R
H460-Luc2
[83]
Palomid 529 Inhibits mTORC1/mTORC2 complex Pre-treatment by P529 led in combination with IR to
radiosensitization of prostate cancer cells and xenografts
LnCaP, 22rv1, DU145,
PC3, LAPC-4, C4-2B
[89]
PI-103 Inhibits both PI3K Pre-treatment by PI-103 led in combination with IR to
radiosensitization of lung cancer cells
A549, H460 [84]
Pre-treatment by PI-103 led in combination with IR to
radiosensitization of breast cancer cells
SKBR3 [85]
Rapamycin Inhibits mTOR signaling pathway Pre-treatment by rapamycin led in combination with IR to
radiosensitization of glioma-initiating cells
GICs [87]
Pre-treatment by rapamycin led in combination with IR to
radiosensitization of lung cancer cells
A549 [88]
Combined treatment with ABT-737 radiosensitized lung
cancer cells and lung xenografts
H460 [101]
STF-62247 Interferes with Golgi-endoplasmic
reticulum transport
Pre-treatment by STF-62247 led in combination with IR to
radiosensitization of renal carcinoma cells
RCC4, 786-O [90]
Temsirolimus Inhibits mTOR signaling pathway Pre-treatment by temsirolimus led in combination with IR
to radiosensitization of renal carcinoma cells
RCC4, 786-O [90]
Z-VAD-FMK Inhibits the action of caspase
proteases
Pre-treatment by Z-VAD-FMK led in combination with IR to
radiosensitization of breast and lung cancer cells via total
inhibition of apoptosis and subsequent activation of
autophagy
MDA-MB-231, H460 [95]
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sirolimus (inhibits mTOR) [90]. A related compound, everolimus,
was reported to sensitize Ras-transformed cells to radiation
in vitro [91] and combined administration of Z-DEVD (caspase-3
inhibitor) together with everolimus into xenografted H460 lung
tumors resulted in superior radiation cytotoxicity compared with
either agent alone [92].
He et al. tested apogossypolone (ApoG2), a small-molecule inhi-
bitor of Bcl-2, to induce radiosensitization both in vitro in nasopha-
ryngeal carcinoma cells and in vivo using mice xenografts. They
proclaimed that ApoG2 inhibited the binding of Bcl-2 to Beclin-1
and induced autophagy [93]. Cruickshanks et al. used lapatinib
(an inhibitor of ErbB1/2/4) and obatoclax (an inhibitor of the
anti-apoptotic Bcl-2/Bcl-XL/Mcl-1 proteins). Such a combination
eradicated multiple breast cancer cells through a mechanism that
involved ER stress signaling and caused DNA damage, which
occurred downstream of ROS generation and autophagy. The
authors point out an essential role of mitochondrial function and
‘‘mitophagy” in radiosensitization by this drug combination, since
over-expression of Mcl-1 protected the cells [94]. The importance
of apoptotic signaling is indisputable. It has been demonstrated
by a study of Moretti et al., who radiosensitized breast tumor
MDA-MB-231 and lung H460 cancer cells by Z-VAD (a pan-
caspase inhibitor), where inhibition of all caspase pathways led
to inhibition of apoptosis. At the same time, a transient burst of
autophagic protein expression was noticed suggesting that autop-
hagy and apoptosis are mutually regulated [95].
On the other hand, Liu et al. used combination of cisplatin and
IR to radiosensitize NSCLCC (A549) and mouse xenografts. Besides
inducing pro-autophagic mechanism, they observed also a
decrease in Bcl-2 expression and a marked upregulation of p21
expression, indicating that activation of pro-apoptotic cell death
mechanism is also involved [96].
Fujiwara et al. presented a different strategy for the tumors that
are resistant to apoptosis induction. Downregulating Akt signaliza-
tion (by specific inhibitor 1L-6-hydroxymethyl-chiro-inositol
2(R)-2-O-methyl-3-O-octadecylcarbonate), they demonstrated
anti-cancer and radiosensitizing effects on malignant glioma
U87-MG and radioresistant U87-MGDEGFR cells [73]. Another
non-apoptotic approach used antisense oligonucleotides againstDNA-PKcs to radiosensitize human malignant glioma cells
(M059K, U373-MG, and T98G) and human fibroblast cells (MRC5)
[97].
Several studies accented potential of vitamin D (vit. D) as well
as its analogs [63]. Calcitriol, or 1,25-dihydroxyvitamin D3 (the
hormonally active form of vit. D – 1,25D3), has been shown to
enhance radiosensitivity of ZR-75-1 breast tumor cells [98]. Bristol
et al. observed minimal apoptosis, but the effects of 1,25D3 on cell
proliferation were proved to be mediated through Akt/mTOR sig-
naling [99]. Besides that, Dr. Gerwitz’s lab provided a proof of prin-
ciple for another vit. D analog (EB 1089). Its pre-incubation before
irradiation converted the senescence response observed with radi-
ation alone to one of the cell death mechanisms [100]. Above that,
they presented an attractive theory on so-called ”autophagic
switch”, which described autophagy as a cytoprotective process
in irradiated breast tumor cells, however, promotion of increased
autophagy can also confer them radiosensitivity. Moreover, both
cytoprotective and cytotoxic autophagy can occur together in one
experimental system as a part of radiation response [98,99].
So far, many modulators of autophagy have been described.
Table 1 summarizes those applied with intention to increase
radiosensitivity of variety of cancer cells in the past few years.
Fig. 1 shows how do they interfere with the process of autophagy.
Autophagy seems to have multiple functions. Besides its cyto-
protective role, autophagy is recognized as cytostatic, non-
protective and cytotoxic process [64]. There are a few compounds
which have a potential to activate autophagy and simultaneously
sensitize cancer cells to IR. For quite a long time it has been
thought that mere induction of cytotoxic autophagy (‘‘autophagic
PCD”) is the reason underlying cancer cells radiosensitization. For
instance, Kim et al. reported that a combined effect of ABT-737
(a Bcl-2 inhibitor) and rapamycin resulted in the effective
radiosensitization of lung cancer cells (H460) and xenografts prob-
ably through death by self-digestion [101]. Such studies underline
the concept of collaborative role of autophagy and apoptosis. Tar-
geting both pathways simultaneously is advantageous due to
synergism.
On the other hand, recently accumulating evidence indicates
that this issue is far more complicated than it seems. A promising
potential of inhibition of both mTOR and apoptotic signaling to
Fig. 1. The process of autophagy and its regulation pathways (framed in blue) in context of radiosensitizers (framed in green and red). The whole machinery of autophagy is
divided into 4 main steps: (1) induction, (2) nucleation, (3) elongation, and (4) maturation; followed by lysis of autophagosomal content. There are plenty of stimuli, which
can trigger autophagy, e.g. starvation, IR, oxygen shortage and DNA damage. These stress stimuli lead to an activation of mTORC complex through PI3K/Akt/mTOR pathway
and subsequent activation of ULK complex, which induces autophagic process. The main regulator of nucleation is class III PI3K, which interacts with Beclin-1 and leads to the
production of second messenger PI(3)P and formation of autophagosome. Other positive regulators are BARKOR, UVRAG and Ambra-1. Proteins Bcl-2, Bcl-XL, Mcl-1 and
RUBICON belong to the negative regulators, which contribute to stopping of nucleation. Proteins ATG7 and ATG10 regulate formation of ATG12, ATG5 and ATG16L complex,
which subsequently activates LC3 complex, a key complex for the final step of autophagosome formation, leading to enclosure of autophagosome membrane. At the end,
lysosome fuses with autophagosome to form autophagolysosome and releases the acidic lysosomal hydrolases degrading the cytosolic content. Radiosensitization of cancer
cells can be achieved by application of both inducers and inhibitors of autophagy. Application of these substances together with IR leads to decreased clonogenic survival of
cancer cells. Majority of inducers (framed in green) activates autophagy in its initial steps, mainly through inhibition of mTOR signaling pathway. On the other hand,
inhibitors of autophagy (framed in red) act in the late phase of autophagic process. Bottom right, inhibitors and inducers with more complex mechanism of autophagy
modulation are listed. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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study of Kim et al., who reported evidence that the pro-apoptotic
proteins of Bcl-2 family (Bax and Bak) play a critical role in medi-
ating the post-radiation mechanism of cell death. Their findings led
to the hypothesis that IR upregulates non-apoptotic PCD (autop-
hagy) in cells which are unable to undergo Bax/Bak-mediated
apoptosis and that radiosensitivity can be increased by attenuating
the given proteins in several cancer cells [102].
Strikingly, other authors such as Kroemer and Levine raised
speculations about the process of ‘‘autophagic PCD”. They admitted
that there were some cancer cells which could be eradicated by
autophagy, especially in vitro. However, this statement cannot be
generalized to all cancer cells and the question of whether mam-
malian cancer cells die by autophagy cannot be answered defini-
tively. In this sense, the term ‘‘autophagic PCD” could be
considered to be a misnomer [103]. Moreover, according to Shen
et al. there are no such studies which could formally establish that
autophagy itself is responsible for cell killing [104]. In addition,
also the method of autophagy assessment should be seriously
taken into account as proposed in guidelines compiled by Klionsky
et al. [105,106]. Increased fluorescent LC3B puncta or changed ratio
in LC3B-I/II is simply not sufficient to claim that autophagy isinduced/reduced. Flux analysis seems to be more convenient test
because it enables dynamic monitoring. Taken together, there is
no definite answer to the question whether the cancer cells die
by or with autophagy and certainly further studies are required
before the end of a term ‘‘autophagic PCD” will be proclaimed.
Concluding remarks
Radiation-induced autophagy is believed to represent a radio-
protective mechanism, thus its inhibition can support radiosensiti-
zation treatment and increase its efficacy. On the other hand, there
is accumulating and clear evidence that IR alone or in combination
with various chemicals induces autophagy, which can result into
increased cell death, e.g. within transformed apoptosis-resistant
cells. Besides that, it will be very important to exploit radiation-
induced autophagy as a therapeutic agent against those tumors,
which are not exactly classified as radiation ‘‘sensitive” or ‘‘resis-
tant” [107].
Obviously, a single universal conclusion can be hardly achieved.
Many reports suggesting radiosensitization of certain cancer cell
types via inhibition of autophagy are opposed by conflicting simi-
lar studies with contradictory results. There is a common presump-
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autophagy. Furthermore, the amount of recently developed induc-
ers of autophagy indicates that the future trend in radiosensitiza-
tion using modulation of autophagy will tend to application of
inducers rather than inhibitors. But, one has to bear in mind that
using inducers of autophagy does not have to lead to radiosensiti-
zation solely via modulation of autophagy and also other than
intrinsic cellular mechanisms might be involved. Such discrepancy
could be reduced with application of coherent methodological
approaches for autophagy assessment. Our field is evolving dra-
matically and what was believed as a good methodology a decade
ago might be considered misleading today. Additionally, the cor-
rect interpretation of data is crucial too. Although a deeper under-
standing of the different roles of autophagy is needed, it is
apparent that its modulation offers a promising and attractive
strategy for tumor treatment along with infectious diseases and
neurodegenerative disorders. Therefore, the future work should
be carried out under isogenic conditions within cells differing only
in a particular gene and with appropriate methods.
In spite of the fact that the fundamental understanding of
autophagy is escalating rapidly, its translation into clinical trials
is draggy. For instance, HCQ has recently shown some promising
results in phase I/II clinical trials [108]. However, it lacks tolerabil-
ity and efficiency for other types of cancers. Such findings drive a
concept of a personalized anti-cancer strategy that should be tai-
lored for an individual patient rather than development of versatile
and all-embracing approach for modulation of autophagy.
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